ALBO - Galera Phase 2 Trial And Other News: The Good Bad And Ugly Of Biopharma
Galera Therapeutics Advances Mid Stage Clinical Trial of GC4419
Galera Therapeutics Inc. (GRTX) reported that it has completed the process of patient enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. The drug candidate is being assessed for safety and anti-cancer efficacy when used in combination with stereotactic body radiation therapy in patients suffering from locally advanced pancreatic cancer.
Phase 1b/2a trial is a randomized study which will focus on determining progression-free survival and overall response rate of the drug candidate. It will also evaluate the safety and tolerability of